SAN DIEGO, January 7, 2021 (GLOBE NEWSWIRE) – BIONANO GENOMICS, INC. (Nasdaq: BNGO), today announced that it plans to offer and sell, subject to the market and other conditions, common shares in a public offering subscription. There can be no guarantee as to whether or when the offer may be completed, or the actual size or terms of the offer. Bionano also expects to give subscribers a 30-day option to purchase up to an additional 15% of the number of common shares offered in the offer, to cover excess lots, if any. All shares of the proposed offer will be sold by Bionano.
Oppenheimer & Co. Inc. is acting as the sole administrative manager of the offering. BTIG, LLC is serving as the principal manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC are serving as co-managers.
The shares are being offered according to a “shelf” registration statement on Form S-3 (File No. 333-245762) previously filed on August 14, 2020 and declared effective by the Securities and Exchange Commission (SEC) on 25 August 2020 A supplement to the preliminary prospectus and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the supplement to the preliminary prospectus and the offer-related prospectus can be obtained from: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26º Floor, New York, New York 10004, by calling 212-667-8055 or [email protected].
Before investing in the offer, you should read the full supplement to the preliminary prospectus and the attached prospectus and the other documents that Bionano filed with the SEC which are incorporated by reference in the supplement to the preliminary prospectus and the attached prospectus, which provide more information about Bionano and the offer.
This press release must not constitute an offer to sell or a solicitation of an offer to buy these securities, nor should there be any sale of such securities in any state or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification. under the securities laws of any state or other jurisdiction.
About Bionano Genomics
Bionano is a genome analysis company that provides tools and services based on its Saphyr system to scientists and doctors who conduct genetic research and patient testing, and provides diagnostic tests for people with autism spectrum disorder (ASD) and others neurodevelopmental deficiencies through its Lineagen businesses. The Saphyr system consists of an instrument, chip consumables, reagents and a set of data analysis tools, as well as genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.
Forward-Looking Statements
This press release contains forward-looking statements in accordance with the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Bionano’s expectations regarding the completion, timing and size of the public offering. Words like “can”, “will”, “wait”, “plan”, “anticipate”, “estimate”, “intend” and similar expressions (as well as other words or expressions that refer to future events, conditions or circumstances) convey uncertainty about future events or results and are intended to identify these forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. Among the factors that may cause actual results to differ materially from those indicated in the forward-looking statements are the risks and uncertainties associated with market conditions and the satisfaction of the usual closing conditions related to the offer, as well as risks and uncertainties associated with Bionano’s businesses. and general financial condition, including the risks and uncertainties described in Bionano’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC, and Bionano’s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this precautionary statement, and Bionano assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Contacts
Company contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]